CYTK$65.94
Chart
Performance
Key Stats
AI CYTK Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralCytokinetics shows potential in its core therapeutic areas but faces significant financial challenges and mixed technical signals. Investors should monitor clinical trial progress and financing activities.
Thematic
The company operates within the growing biopharmaceutical sector, focusing on cardiovascular diseases which have significant unmet needs. Success in clinical trials and market adoption of its therapies are key thematic drivers.
Fundamental
Cytokinetics faces considerable financial headwinds, characterized by significant losses, negative earnings, and substantial debt. While revenues are growing, they are not yet sufficient to offset high operating expenses and R&D costs.
Technical
The stock's short-term technicals are mixed. While it shows some recent upward momentum, it is trading below key moving averages, and oscillators suggest a neutral to slightly bearish short-term outlook.
| Factor | Score |
|---|---|
| Biotechnology & Pharmaceuticals Growth | 80 |
| Cardiovascular Disease Market | 85 |
| Drug Development & Clinical Trials | 70 |
| Competition Landscape | 60 |
| Partnerships and Collaborations | 70 |
| Factor | Score |
|---|---|
| Valuation | 15 |
| Profitability | 5 |
| Growth | 75 |
| Balance Sheet Health | 30 |
| Cash Flow | 10 |
| Earnings Per Share (EPS) | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-Term Performance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Focus on Late-Stage Biopharmaceutical Development
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for debilitating diseases. Its focus on muscle activators and inhibitors targets significant unmet medical needs in areas like heart failure and hypertrophic cardiomyopathy. The company has a pipeline of drug candidates in various clinical trial phases (Phase I, II, and III), indicating a commitment to innovation and product development. Strategic alliances and collaborations, such as with Ji Xing Pharmaceuticals Limited, can accelerate development and expand market reach.
Revenue Growth and Emerging Market Potential
While recent quarterly revenue figures are low, the company's focus on commercialization of its pipeline drugs, such as aficamten (in Phase III for hypertrophic cardiomyopathy), suggests significant future revenue potential. The collaboration for aficamten in Japan indicates an expansion strategy into key international markets. Investors should monitor the progress of clinical trials and regulatory approvals as key drivers for future revenue and profitability.
Bearish Points (5)
Persistent Net Losses and Negative Margins
Cytokinetics has consistently reported significant net losses, with a net income of -$589.53 million in Q4 2024. The net margin remains deeply negative, reflecting the high costs associated with drug development without substantial commercial revenue. Gross profit is also negative (-$320.93 million in Q4 2024), indicating that current revenues do not cover the cost of goods sold or associated R&D expenses, a typical characteristic of pre-revenue biopharma companies.
High Price-to-Sales Ratio
The company's trailing Price-to-Sales (P/S) ratio is very high, indicated by values like 304.1 (2024) and 591.7 (2023). This reflects the current limited revenue base relative to its market capitalization. The P/E ratio is also not applicable due to persistent losses. These valuation metrics highlight the speculative nature of investing in the company at this stage, as future success hinges on the successful commercialization of its pipeline.
Calendar
August 2025
8
Next Earnings Date
H: $-0.35
A: $-1.35
L: $-1.60
H: 15.00M
A: 1.95M
0Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Seasonals
Price Target
72.55 USD
The 39 analysts offering 1 year price forecasts for CYTK have a max estimate of 120.00 and a min estimate of 41.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in muscle biology, developing novel therapeutics for muscle disorders including cardiovascular conditions, aligning closely with Cytokinetics' focus on muscle activators and inhibitors. [5, 7, 17]
Weight: 90
Top competitor in the biotechnology field, specifically focused on heart disease, which is a primary therapeutic area for Cytokinetics. [5, 7]
Weight: 88
Acquired MyoKardia, which developed mavacamten, a cardiac myosin inhibitor that directly competes with Cytokinetics' aficamten for hypertrophic cardiomyopathy (HCM). [6, 9]
Weight: 85
Clinical-stage life sciences company focused on developing therapies for heart disease, including heart failure, a key area for Cytokinetics. [18]